Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Cancer Immunotherapy Conference

Emerging Biology, Targets and Strategies

March 7 – 9, 2016 | Moscone North Convention Center

Learn More | Register Today!

Cancer immunotherapy, hailed as the biggest breakthrough in modern cancer treatment, has quickly permeated mainstream basic and clinical research. With vast excitement seen over the past few years stirred by remarkable clinical efficacy of immunotherapy agents, the emergence and rapid growth of biotechs and pharmaceutical partnering, and recent regulatory approvals of checkpoint inhibitors and T-cell engagers, it has become clear that immuno-oncology research and the development of immunotherapies and their combinations will continue to revolutionize cancer treatment.

Cambridge Healthtech Institute’s inaugural Cancer Immunotherapy meeting will convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss current challenges and opportunities – from discovery immuno-oncology to clinical studies; share latest technologies and development approaches; discuss advances in adoptive T-cell therapies and combinations, as well as to provide updates on clinical findings.

Preliminary Agenda

HARNESSING NK CELLS FOR NEW ADOPTIVE CELL THERAPIES

Enhancing NK Cell Function for Transplantation and Cancer Therapy

Jeffrey Miller, M.D., Professor, Medicine; Deputy Director; Roger L. and Lynn C. Headrick Chair in Cancer Therapeutics, University of Minnesota Cancer Center

Immunosurveillance and Immunotherapy of Cancer Mediated by Natural Killer Cells

David H. Raulet, Ph.D., CH Li Professor of Immunology and Pathogenesis; Co-Chair, Department of Molecular and Cell Biology, University of California, Berkley

Utilizing Function-Enabled NK Cells for Cancer Immunotherapy

Todd A. Fehniger, M.D., Ph.D., Associate Professor, Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia Section, Washington University School of Medicine

NK Adoptive Transfer and mAb Combination for Colon Cancer

Nina D. Shah, M.D., Medical Director and Assistant Professor, Stem Cell Transplantation Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Enhancing Antibody-Directed Innate Immunity to Improve Cancer Outcome

Paul M. Sondel, M.D., Ph.D., Reed and Carolee Walker Professor of Pediatrics and Human Oncology; Head, Division of Pediatric Hematology, Oncology and BMT; University of Wisconsin

ADVANCES IN ADOPTIVE T-CELL THERAPY

CAR T-Cells as Immunotherapy: Where Are We Now?

Marcela Valderrama Maus, M.D., Ph.D., Director, Cellular Immunotherapy, Massachusetts General Hospital Cancer Center; Member of the Faculty, Harvard Medical School

The ImmTAC Technology: A Cutting Edge Immunotherapy for Cancer Treatment

Martina Canestraro, Ph.D., Scientist, Cell biology, Immunocore Limited

Panel Discussion: Current Challenges and Opportunities for CAR T-Cell Therapy
This panel discussion will tackle current challenges and emerging opportunities within the rapidly emerging space of chimeric antigen receptor (CAR) T-cell therapy. Topics will include, but are not limited to:

– Novel and emerging antigens for targeting

– Challenges and opportunities in targeting solid tumors

– Approaches for avoiding or controlling cytokine syndrome

– Enhancing expansion and persistence of T-cells

– Combination strategies to combat tumor microenvironment

Moderator: James Smothers, Ph.D., Senior Director and Head, Discovery, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline

Panelists:

-Richard Morgan, Ph.D., Vice President, Immunotherapy, bluebird bio

-David M. Spencer, Ph.D., CSO, Bellicum Pharmaceuticals, Inc.

– Philippe Duchateau, Ph.D., CSO, Cellectis SA

– Marcela Valderrama Maus, M.D., Ph.D., Director, Cellular Immunotherapy, Massachusetts General Hospital Cancer Center; Member of the Faculty, Harvard Medical School

EMERGING STRATEGIES FOR CHECKPOINT COMBINATION THERAPY

Cyclic Dinucleotides and Cancer Vaccine Development

Thomas W. Dubensky, Jr., Ph.D., CSO, Aduro Biotech

OX40 Agonist Combined with PD-1 and TGFb Receptor Blockade

Andrew D. Weinberg, Ph.D., Chief, Laboratory of Basic Immunology, Providence Cancer Center

Pre-Clinical Evaluation of an Agonist Antibody Targeting ICOS

Robert Mabry, Ph.D., Director, Protein Sciences and Antibody Technology, Jounce Therapeutics

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells

John C. Lin, Ph.D., Senior Vice President & CSO, Cancer Immunotherapy, Pfizer

Combination Immunotherapies – Opening the Gate: Increasing Tumor Infiltrating Activated T-Cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies

Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals

Checkpoint Immunotherapy Combinations with Small Molecules

James Smothers, Ph.D., Senior Director and Head, Discovery, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline

NOVEL TARGETS FOR IMMUNOTHERAPY DEVELOPMENT AND SYNERGISTIC COMBINATIONS

4-1BB as an Immune Target

Holbrook Kohrt, M.D., Ph.D., Assistant Professor, Medicine (Oncology), Stanford University Medical Center

Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1

Xingxing Zang, Ph.D., Associate Professor, Microbiology, Immunology and Medicine, Albert Einstein College of Medicine

oxMIF as a New Therapeutic Target in Cancer

Michael Thiele, Ph.D., Manager R&D, Research & Innovation, Baxalta Innovations GmbH

TECHNOLOGICAL INNOVATIONS ENABLING DISCOVERY

New Insight into Mode of Action of Checkpoint Inhibitors via QC Cell Based Assays

Natko Nuber, Ph.D., Lab head, Novartis Biologics, Novartis

Presentation to be Announced

Sponsored by Oncodesign

Charles River no taglineCombination Immune Checkpoint Inhibitors for the Treatment of Colon Carcinoma in Humanized NSG Mice.

Sponsored by Charles River

Presentation to be Announced

Sponsored by Cellectis

Biomarkers for Cancer Immunotherapy Symposium

Predictive and Prognostic Biomarkers for Immuno-oncology

March 10-11, 2016 | Hilton San Francisco Union Square

Learn More | Register Today!

Cancer immunotherapy research continues to charge forward at a rapid pace. There have been advances in existing technologies, mounting research in target discovery, and better understanding of molecular mechanisms. Still, much work needs to be done before immunotherapies are ready for standard use and biomarkers will play a pivotal role.

Cambridge Healthtech Institute’s Inaugural Biomarkers for Cancer Immunotherapy will showcase research on both predictive and prognostic biomarkers while addressing the biggest questions around predictors of immune response. Focus will be given to clinical trial case studies, global vs. type-specific markers, and molecular mechanisms. Overall, this event will provide solutions to bridge the gap between biomarkers and therapy selection.

Preliminary Agenda

PREDICTIVE AND PROGNOSTIC BIOMARKERS FOR IMMUNO-ONCOLOGY

Cancer Immunotherapy Biomarkers: Lessons from Clinical Trials

Lisa H. Butterfield, Ph.D., Professor, Medicine, Surgery and Immunology; Director, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh

An Assay for Simultaneous Measurement of Subpopulations of Tumor Infiltrating Lymphocytes

Kurt Schalper, M.D., Ph.D., Associate Research Scientist, Pathology, Yale School of Medicine

The Role of Global Immunocompetence In Cancer Immunotherapy

Holden Maecker, Ph.D., Associate Professor, Microbiology and Immunology; Director, Human Immune Monitoring Center, Stanford University

Peritumoral vs. Intratumoral Cells in Outcome Coordination

Paul Tumeh, M.D., Assistant Professor, Department of Medicine, University of California Los Angeles

Tissue-Based Analyses to Guide Immunotherapy for Lymphoma

Scott Rodig, M.D., Ph.D., Hematopathologist, Department of Pathology, Brigham and Women’s Hospital

PREDICTORS FOR CHECKPOINT INHIBITORS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Luis Diaz, M.D., Associate Professor, Oncology, John Hopkins Kimmel Cancer Center

PD-L1/PD-1 Tumor Biology

Kathleen Mahoney, M.D., Ph.D., Instructor, Medicine, Hematology Oncology, Beth Israel Deaconess Medical Center

THE ROLE OF THE TUMOR MICROENVIRONMENT

Imprime PGG and the Tumor Microenvironment

Jeremy R. Graff, Ph.D., Senior Vice President, Research, Pharmaceutical Group, Biothera, Inc.

Genomic Approaches to Deciphering Protective Immune Mechanisms in Cancer

Brad Nelson, Ph.D., Director, Deeley Research Centre, BC Cancer Agency

IMMUNOTHERAPY CLINICAL TRIALS

Immunotherapy at a Tipping Point: DPV-001 – A DC-Targeted Strategy with More than 100 Cancer Antigens, Multiple TLR Agonists and Damps Induces Broad-Spectrum Anti-Cancer Immunity in Patients with Cancer

Bernard A. Fox, Ph.D., Harder Family Chair for Cancer Research, Member & Chief, Laboratory of Molecular & Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center; CEO, UbiVac

Combinations with CRS-207, a Live-Attenuated Listeria Monocytogenes Expressing Mesothelin

Dirk G. Brockstedt, Ph.D., Senior Vice President, Research & Development, Aduro BioTech, Inc.

Product Characteristics and Pharmacodynamic Biomarker Profile of Patients Receiving Anti-CD19 CAR T Cell Therapy: Correlates of Clinical Response

Margo Roberts, Ph.D., CSO, Kite Pharma, Inc.

ESTABLISHING COMPANION DIAGNOSTICS ACROSS TARGETED IMMUNOTHERAPIES

Establishing a PD-L1 Diagnostic for Nivolumab, a Novel Immune PD-1 Checkpoint Inhibitor for the Treatment of Cancer

Steven D. Averbuch, M.D., Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb Company

A Critical Appraisal of Biomarkers for Immune Therapy: The Pathologist’s Perspective

Robert A. Anders, Ph.D., Associate Professor, Pathology, Johns Hopkins School of Medicine; Director, Liver Pathology, Division of Gastrointestinal and Liver Pathology, Johns Hopkins Hospital

Talk Title to be Announced

Abigail McElhinny, Ph.D., Vice President, Assay and Reagent Development, Ventana

Developing an Immunohistochemistry Test for “Programmed Cell Death 1 Ligand” (PD-L1) as a Companion Diagnostic for Pembrolizumab

Kenneth Emancipator, M.D., Executive Medical Director, Molecular Biomarkers and Diagnostics, Merck Research Laboratories

PANEL DISCUSSION
Moderator to be Announced

Panelists:

-Robert A. Anders, Ph.D., Associate Professor, Pathology, Johns Hopkins School of Medicine; Director, Liver Pathology, Division of Gastrointestinal and Liver Pathology, Johns Hopkins Hospital

-Steven D. Averbuch, M.D., Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb Company

-Abigail McElhinny, Ph.D., Vice President, Assay and Reagent Development, Ventana

-Kenneth Emancipator, M.D., Executive Medical Director, Molecular Biomarkers and Diagnostics, Merck Research Laboratories

GET THE BEST VALUE WITH TRI-CON ALL ACCESS!
Includes access to one conference, one symposium, and two short courses.

Recommended All Access Package:

Cancer Immunotherapy Conference

Biomarkers for Cancer Immunotherapy Symposium

SC10: Development of Cell-Based Bioassays for Checkpoint Inhibitor Targeting | Learn More

Natko Nuber, Ph.D., Lab Head, Novartis Biologics, Novartis

SC21: Best Practices in Personalized and Translational Medicine | Learn More

Julio Fernandez, Ph.D., Principal Scientist, Pfizer